A novel improved therapy strategy for diabetic nephropathy

Cancer Therapy Based on Nanomaterials and Nanocarrier Systems

(2010) Weili Qiao et al.   Journal of Nanomaterials

Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation

(2009) Takanori Matsui et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

(2009) Yuji Ishibashi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets

(2009) Karly Sourris et al.   CURRENT DRUG TARGETS

Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach

(2009) Imtiaz Shah et al.   CURRENT MEDICINAL CHEMISTRY

Advanced glycation end-products: Implications for diabetic and non-diabetic nephropathies

(2009) M. Daroux et al.   DIABETES & METABOLISM

Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions

(2009) Pitchai Balakumar et al.   PHARMACOLOGICAL RESEARCH

Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression

(2009) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

Role of AGEs in Diabetic Nephropathy

(2008) Kei Fukami et al.   CURRENT PHARMACEUTICAL DESIGN

Diabetic nephropathy: Important pathophysiologic mechanisms

(2008) G. Soldatos et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Targeting cancer cells with biotin–dendrimer conjugates

(2008) Wenjun Yang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression

(2007) Sho-ichi Yamagishi et al.   MICROVASCULAR RESEARCH